Letter to the Editor

Spirulina: A promising opportunity to overcome neuropathic pain challenges in chronic kidney disease patients

To Editor,

Neuropathic pain management presents significant challenges due to its multifactorial etiology and complex underlying pathways. This is particularly evident in patients with chronic kidney disease (CKD), who require meticulous drug selection and dose adjustment to avoid further renal compromise. Peripheral polyneuropathy is the most prevalent complication associated with CKD, affecting over 60% of patients and contributing to disability and diminished quality of life.¹ First-line treatments for neuropathic pain syndromes, including tricyclic antidepressants, gabapentinoids, and serotonin-norepinephrine reuptake inhibitors, are commonly recommended. However, the inherent complexity of neuropathic pain and the poor tolerability of these medications in CKD patients underscore the growing need for novel therapeutic agents.²

Spirulina, a filamentous cyanobacterium, is rich in bioactive compounds such as phycocyanin, polyphenols, β-carotene, γ-linolenic acid, and antioxidant enzymes, including superoxide dismutase (SOD) and catalase. These constituents exhibit potent anti-inflammatory and antioxidant effects by inhibiting NF-κB and COX-2 signaling pathways and reducing inflammatory cytokines like TNF-α and IL-6.³ The U.S. Food and Drug Administration (FDA) recognizes Spirulina as a safe dietary supplement.⁴ Nonetheless, caution is warranted regarding its potential interactions with cytochrome P450 isoenzymes.⁵

Emerging evidence suggests that Spirulina may offer benefits in ameliorating neuropathy. Preclinical studies have demonstrated its positive effects on diabetic neuropathy, sciatic neuropathic pain, and chemotherapy-induced neuropathy.^6-8 Notably, dysregulation of the Nrf2 pathway and oxidative stress are central to CKD progression and its complications. From a neuroprotective perspective, Spirulina activates Nrf2/HO-1 and BDNF/CREB signaling pathways, serving as a potential therapeutic target for neuropathic pain management by enhancing antioxidant defense, neuronal survival, and neurogenesis. It also suppresses microglial activation and inflammatory cytokines, thereby mitigating neuroinflammation and protecting neurons from oxidative stress-induced apoptosis.^9-12

Numerous studies have further elucidated the nephroprotective properties of Spirulina.Its efficacy and safety in CKD patients have been substantiated.^13,14 Specifically, Spirulina significantly reduces oxidative stress markers such as malondialdehyde (MDA) and reactive oxygen species (ROS), boosts antioxidant enzyme activity in renal tissue, inhibits inflammatory mediators including TNF-α, IL-6, and TGF-β implicated in renal inflammation and fibrosis, and modulates fibrosis and apoptosis pathways to protect against CKD progression.¹⁵

Together, these molecular mechanisms support spirulina’s dual neuro- and nephroprotection potential in CKD patients experiencing neuropathic pain.Although it has not yet garnered widespread clinical attention, Spirulina's valuable nephroprotective and neuroprotective attributes merit further investigation as a novel, efficacious complementary treatment for neuropathy in this population. Robust validation through targeted clinical trials is imperative. We posit that Spirulina represents a promising avenue to enhance the quality of life for these patients. Your journal would lead innovative research by highlighting this strategy to address this pressing clinical challenge.

Competing Interests

The author declares that she has no conflict of interest.

Ethical Approval

Not applicable.

References

1. Gondhali G, Kundalwal A, Takalkar AA. Peripheral neuropathy in chronic kidney diseases: prevalence and its correlates. Int J Adv Med 2020; 7:22-6. doi: 10.18203/2349-3933.ijam20195621 [Crossref] [ Google Scholar]
2. Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther 2017; 6:35-42. doi: 10.1007/s40122-017-0087-0 [Crossref] [ Google Scholar]
3. Mousavi S, Yegdaneh A, Shirani M, Feizi A, Ghanadian M. Spirulina supplementation and its effects on inflammation and oxidative stress: a systematic review and meta-analysis on randomized clinical trials. J Funct Foods 2025; 131:106945. doi: 10.1016/j.jff.2025.106945 [Crossref] [ Google Scholar]
4. Dąbrowska NK, Marcinkowski K, Mazur A, Mazur S, Madera M, Strus K. Spirulina maxima supplementation: benefits and limitations–results of latest studies. J Pre Clin Clin Res 2024; 18:195-200. doi: 10.26444/jpccr/189444 [Crossref] [ Google Scholar]
5. Savranoglu S, Tumer TB. Inhibitory effects of Spirulina platensis on carcinogen-activating cytochrome P450 isozymes and potential for drug interactions. Int J Toxicol 2013; 32:376-84. doi: 10.1177/1091581813503887 [Crossref] [ Google Scholar]
6. Safakhah HA, Tamimi F, Moradi Kor N, Bandegi AR, Ghanbari A. Hypoalgesic effect of Spirulina platensis on the sciatic neuropathic pain induced by chronic constriction injury in male rats. Biomed Res Ther 2018; 5:2671-9. doi: 10.15419/bmrat.v5i9.477 [Crossref] [ Google Scholar]
7. Ghosh M, Tasnim SF, Roy S, Ghash S, Sathi MN, Jahan N. Effects of Spirulina platensis on hyperglycemia and mechanical allodynia in streptozotocin-induced diabetic rats: Spirulina platensis on hyperglycemia and mechanical allodynia. Journal of the Medical College for Women & Hospital 2024; 20:56-63. doi: 10.3329/jmcwh.v20i2.77290 [Crossref] [ Google Scholar]
8. Le Gouill-Jaijarat C, Péréon Y, Leroy M, Lépine O, Loloum A, Peluchon C. PROPERTY: study protocol for a randomized, double-blind, multicenter placebo-controlled trial assessing neurotoxicity in patients with metastatic gastrointestinal cancer taking PHYCOCARE® during oxaliplatin-based chemotherapy. Trials 2023; 24:50. doi: 10.1186/s13063-023-07071-z [Crossref] [ Google Scholar]
9. Koh EJ, Seo YJ, Choi J, Lee HY, Kang DH, Kim KJ. Spirulina maxima extract prevents neurotoxicity via promoting activation of BDNF/CREB signaling pathways in neuronal cells and mice. Molecules 2017; 22:1363. doi: 10.3390/molecules22081363 [Crossref] [ Google Scholar]
10. Almeida T, Manfroi G, Silva S, Beggiora P, Schwingel D, Bertolin TE. Exploring the neuroprotective effects of Spirulina platensis: insights into hemorrhagic volume and histological outcomes. Cureus 2023; 15:e42078. doi: 10.7759/cureus.42078 [Crossref] [ Google Scholar]
11. Sorrenti V, Castagna DA, Fortinguerra S, Buriani A, Scapagnini G, Willcox DC. Spirulina microalgae and brain health: a scoping review of experimental and clinical evidence. Mar Drugs 2021; 19:293. doi: 10.3390/md19060293 [Crossref] [ Google Scholar]
12. Aranda-Rivera AK, Cruz-Gregorio A, Pedraza-Chaverri J, Scholze A. Nrf2 activation in chronic kidney disease: promises and pitfalls. Antioxidants (Basel) 2022; 11:1112. doi: 10.3390/antiox11061112 [Crossref] [ Google Scholar]
13. Rodríguez-Salgueiro S, Ramírez-Carmenate Z, González-Núñez L. An update on potential applications of Spirulina sp and C-phycocyanin to treat kidney diseases. Ann Res Antioxid 2017; 2:e04. [ Google Scholar]
14. Memije-Lazaro IN, Blas-Valdivia V, Franco-Colín M, Cano-Europa E. Arthrospira maxima (Spirulina) and C-phycocyanin prevent the progression of chronic kidney disease and its cardiovascular complications. J Funct Foods 2018; 43:37-43. doi: 10.1016/j.jff.2018.01.013 [Crossref] [ Google Scholar]
15. Abouzed TK, Soliman MM, Khatab SA, Gouda WM, Eldomany EB, Dorghamm DA. The protective impacts of Spirulina platensis against cisplatin-induced renal injury through the regulation of oxidative stress, pro-inflammatory cytokines and Bax/Bcl2. Toxicol Res (Camb) 2022; 11:169-78. doi: 10.1093/toxres/tfab128 [Crossref] [ Google Scholar]